MIR1-1HG
Uncharacterized protein MIR1-1HG
Also known as: MI1HG_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for MIR1-1HG in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
117 residues, UniProt reviewed canonical sequence.
>Q9H1L0|MIR1-1HG
1 MPSCSCALMA PCGPAAGPAA VERTQQVARG EPGSARGQLQ VSPEMSITHK EKENAHLKEI
61 LLFVNAEAFS QPQPHSAPVC EGQQLTGKFS TSVLTRAGGD ASPCSWERLL CYGWSHCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MIR1-1HG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MIR1-1HG as an antibody target. Whether an autoantibody or antibody against MIR1-1HG could matter depends on whether native MIR1-1HG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MIR1-1HG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MIR1-1HG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...